Lipid Disorders
Latest News
Hypertriglyceridemia in Young Adults Raises Red Flag
High triglycerides are linked to risk for type 2 diabetes.
Latest News
Higher HDL Tied to Prediabetes Reversion — Up to a Point
After a median follow-up of nearly 3 years, 43% of patients with prediabetes had a reversion to normoglycemia; those with higher HDL-C levels had...
Latest News
Lipids and Dementia: A Complex and Evolving Story
“It depends on what lipids you’re measuring, what you’re using to measure those lipids, what age the person is, and...
Latest News
MASLD often is worse in slim patients
These slim patients with MASLD were most often young patients, for the most part female, and less likely to present with symptoms of metabolic...
From the Journals
Vegan diet confers cardiometabolic benefits
“Clinicians may consider recommending plant-based diets to reduce cardiometabolic risk factors, as well as aligning with environmental benefits...
Conference Coverage
New PCSK9 inhibitor allows 3-month treatment intervals
Recaticimab, an investigational PCSK9 inhibitor, has shown durable lowering of low-density lipoprotein cholesterol with injection frequencies of 1...
Latest News
Bariatric surgery still best option for some with obesity
“Sometimes we might need to go straight to surgery instead of going through medications first, because it may be the most effective and evidence-...
Latest News
PREVENT: AHA’s new risk calculator incorporates CKM health
PREVENT is for use in adults aged 30-79 years and estimates the 10- and 30-year risk of total CVD including, for the first time, heart failure.
Conference Coverage
Promising first results with DNA editing to lower LDL
The first in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial...
Conference Coverage
Pharmacist-based strategy places more patients on statins
In two studies run in parallel fashion, testing different strategies, automatic referral to a pharmacist was superior to EHR alerts for increasing...
Conference Coverage
Sustained reductions in Lp(a) achieved with novel siRNA drug
“At the highest doses, lepodisiran is not just lowering Lp(a), it appears to be getting rid of it.”